Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.32
$0.25
$1.19
$17.03M1.19172,213 shs4.12 million shs
Invitae Co. stock logo
NVTA
Invitae
$0.00
$0.00
$0.02
$0.02
$80K1.5923.72 million shs75 shs
OpGen, Inc. stock logo
OPGN
OpGen
$4.70
$4.76
$0.53
$5.25
$47.32M-1.668,920 shs6 shs
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
$0.07
$0.06
$0.06
$3.23
N/A0.981.04 million shsN/A
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%0.00%-71.49%
Invitae Co. stock logo
NVTA
Invitae
0.00%0.00%0.00%0.00%-25.00%
OpGen, Inc. stock logo
OPGN
OpGen
0.00%-1.67%-3.69%+13.25%+55.32%
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
0.00%0.00%0.00%0.00%-96.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
N/AN/AN/AN/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/AN/AN/AN/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
0.00
N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
0.00
N/AN/AN/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
Invitae Co. stock logo
NVTA
Invitae
$481.58M0.00N/AN/A$0.42 per share0.00
OpGen, Inc. stock logo
OPGN
OpGen
$2.67M17.70N/AN/A($11.55) per share-0.41
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
$730K0.40N/AN/A$4.04 per share0.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A
Invitae Co. stock logo
NVTA
Invitae
-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/A
OpGen, Inc. stock logo
OPGN
OpGen
-$32.67MN/A0.00N/A-1,140.36%N/A-287.58%N/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
-$21.24M-$6.440.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
N/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
Invitae Co. stock logo
NVTA
Invitae
N/A
2.39
2.25
OpGen, Inc. stock logo
OPGN
OpGen
N/A
5.45
5.45
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
Invitae Co. stock logo
NVTA
Invitae
61.28%
OpGen, Inc. stock logo
OPGN
OpGen
2.68%
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
15.25%

Insider Ownership

CompanyInsider Ownership
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
Invitae Co. stock logo
NVTA
Invitae
0.74%
OpGen, Inc. stock logo
OPGN
OpGen
43.80%
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
4.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
Invitae Co. stock logo
NVTA
Invitae
1,700267.01 million284.37 millionOptionable
OpGen, Inc. stock logo
OPGN
OpGen
10010.07 million4.70 millionNot Optionable
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
194.44 million4.24 millionOptionable

Recent News About These Companies

TFF Pharmaceuticals approves dissolution plan
The TFFP Stock Mystery: Why Did TFFP Plunge Today?
TFF Pharmaceuticals Shares Fall 66%; Company to Wind Down
TFF Pharmaceuticals terminates employees, to wind down operations
TFF Pharmaceuticals to Dissolve and Liquidate Assets
TFF Pharmaceuticals Announces It Will Wind Down Operations
Post-COVID Trends in Biopharma Contract Manufacturing
The Yadot Group to Acquire Experiential Agency Socials Dallas

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Invitae stock logo

Invitae NYSE:NVTA

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

OpGen stock logo

OpGen NASDAQ:OPGN

$4.70 0.00 (0.00%)
As of 07/18/2025

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

TFF Pharmaceuticals stock logo

TFF Pharmaceuticals NASDAQ:TFFP

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.